Design and rationale of RECOVER-AUTONOMIC: a randomized platform trial evaluating interventions for Long COVID postural orthostatic tachycardia syndrome - PubMed
9 hours ago
- #Clinical Trial
- #POTS
- #Long COVID
- RECOVER-AUTONOMIC is a randomized platform trial evaluating interventions for Long COVID-related postural orthostatic tachycardia syndrome (POTS).
- The trial assesses three interventions: coordinated nonpharmacologic care, intravenous immunoglobulin (IVIG), and ivabradine.
- Primary endpoint measures change in orthostatic intolerance symptoms using the Orthostatic Hypotension Questionnaire/Orthostatic Intolerance Questionnaire.
- Secondary endpoints include quality of life, functional performance, symptom burden, and safety.
- Exploratory endpoints involve autonomic function testing, wearable sensor data, and biomarker profiling.
- The trial aims to provide evidence for treating POTS in Long COVID patients.
- Trial registration details and protocol are available on ClinicalTrials.gov and the RECOVER website.